ArticleAmerican journal of cancer research2024
Efficacy of abiraterone combined with prednisone in castration-resistant prostate cancer and its impact on miR-221/222 expression.
Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of multi‑omics in advancing the understanding and treatment of prostate cancer (Review).Molecular medicine reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the therapeutic efficacy of abiraterone combined with prednisone in patients with castration-resistant prostate cancer (CRPC) and investigate its effects on miR-221/222 expression.
methodsA retrospective cohort of 43 CRPC patients from Henan Provincial People's Hospital, People's Hospital of Zhengzhou University was divided into two groups: the treated group (n=22, treated with abiraterone and prednisone) and the control group (n=21, treated with prednisone acetate alone). Expression of miR-221/222 was quantified in CRPC cell lines using quantitative fluorescence polymerase chain reaction.
resultsThe treated group demonstrated significantly higher rates of bone pain relief and prostate-specific antigen (PSA) response compared to the control group (P=0.032, P=0.022, respectively). Post-treatment, the treated group also showed increased Karnofsky Performance Status scores and reduced plasma testosterone levels relative to controls (P=0.021, P=0.016). There was no significant difference in the incidence of adverse reactions between the treated group (31.82%) and the control group (28.57%) (P=0.125).
conclusionsAbiraterone combined with prednisone effectively relieves bone pain and improves PSA response rates in CRPC patients, suggesting benefits in enhancing quality of life and reducing testosterone levels without increasing adverse reactions. This therapy appears to have a safety profile comparable to that of conventional treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.